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INTRODUCTION
Historic outlook of autoantibodies 
screening using HEp-2 in Brazil
Technological and scientific development has promoted chan-
ges in laboratory tests that affect important parameters for 
clinical interpretation, such as positive and negative predictive 
values, sensibility and specificity. An excellent example of this 
situation is the antinuclear antibody (ANA) screening using 
the indirect immunofluorescent (IIF) technique, also known 
as antinuclear factor, today called “screening for antibody 
against cell antigens” in serum of patients under autoimmune 
disease suspicion. It is an excellent test to track autoantibodies 
that, along the last decades, has been technically changed to 
provide a progressively higher sensitivity. As a consequence, 
the antibody screening against cell antigens also started to 
present lower specificity.1
However, the increment of ANA-IIF test sensitivity using 
HEp-2 cells also brought up a loss in specificity, as some 
individuals without clinical or laboratory evidence of autoim-
mune disease also presented positive results in HEp-2 cells, 
requiring a strict interpretation of serological findings.2 The 
high frequency of positive results in healthy individuals or 
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ABSTRACT
Objective: The Third Brazilian Consensus for autoantibodies Screening in HEp-2 cells had as purpose the evaluation 
of difficulties in the accomplishment of the 2nd Consensus recommendations that took place in the year of 2002, the 
discussion of strategies for quality control of the assay and the promotion of an update of the clinical associations of 
the several immunofluorescent patterns. Methods: Several ANA experts from university centers and private laboratories 
in different areas in Brazil joined the workshop in Goiânia on 2008 April 13 and 14 with the purpose of discussing 
and approving the recommendations for standardization, interpretation and use of the test by physicians. Commercial 
representatives of different ANA slide brands were also invited as listeners to the workshop. Results and Conclusions: 
The 3rd Consensus emphasized the need for quality control in indirect immunofluorescent since there is a considerable 
heterogeneity of available microscopes and reagents. It also promoted adaptations in the previously approved terminol-
ogy used to classify the different patterns and finally updated the clinical associations of the several patterns with the 
purpose of providing guidance for interpretation of the assay by clinical pathologists and assistant physicians. 
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individuals with vague clinical manifestations has revealed a 
situation called “syndrome of idiopathic antinuclear antibody”.1 
Loss of specificity in this test has also been aggravated  due to 
the fact that a wide range of expert physicians started to use 
it. Initially, rheumatologists and nephrologists were the main 
users of this exam and, due to a familiarity with it and their 
patients’ characteristics, they had more chances to request this 
test for those who really had an autoimmune history.
Today, ANA-IIF using HEp-2 is a test requested with fewer 
criteria by a wide range of specialists, who obviously see to 
different patients, in which autoimmune rheumatic disease 
diagnosis is less prevalent. Thus, the chance of positive results 
in healthy individuals, or with low expressive clinical presenta-
tions, became higher. Some elements are important to suitable 
value the ANA-IIF in HEp-2 test. Firstly, this test should be 
requested only under convincing suspicion of autoimmune 
disease. Requesting this test for a patient presenting uncertain 
complaints frequently will bring more confusion to the clini-
cal judgment, as a positive result does not necessary mean 
autoimmunity. A second point to be considered is ANA-IIF in 
HEp-2 titer: in general, autoimmune patients tend to present 
moderate (1/160 and 1/320) and high (≥ 1/640) titers, while 
healthy individuals tend to present low titers (1/80).3 However, 
both situations may present exceptions.4 Another important 
point is the fluorescence pattern that shows the identity of 
autoantibody(ies) in consideration;5 it should be carefully 
analyzed taking in account the experience and expertise of 
observer, as well as the capacity to reproduce the pattern using 
kits by different manufacturers. 
Autoantibodies against some antigens have specific asso-
ciation with certain autoimmune diseases or to autoimmunity 
state while others occur indiscriminately in autoimmune and 
non-autoimmune individuals. So, certain fluorescence patterns 
are more specific to autoimmune disease while others happen 
frequently in healthy individuals or in patients with other non-
autoimmune diseases.1
Another point to be considered is that the physiological 
autoimmunity level, or basal level, may fluctuate depending 
on the overcharges the immune system is exposed to. The 
autoantibody presence broken out by infections, drugs or 
neoplasia is well demonstrated. High prevalence of autoanti-
bodies in patients with HIV (human immunodeficiency virus) 
and other lymphotropic virus6 has been clearly demonstrated. 
Therefore, an important point to take into consideration when 
evaluating a positive finding of ANA-IIF using HEp-2 cells 
refers to the possibility of recent viral infections, drug use and 
neoplasic processes.
Several evidences demonstrate that autoantibodies fre-
quently precede clinical diagnosis of autoimmune diseases.7 
A positive ANA-IIF using HEp-2 test may precede clinical 
systemic lupus erythematosus (SLE) in up to nine years. 
Almost 80% of patients with SLE present positive ANA-IIF 
in HEp-2 before the first symptoms. Although in a lower per-
centage, it is also valid for several autoantibodies specific for 
this disease, such as double stranded anti-dNA and anti-Sm. 
Consequently, another possibility to be considered facing a 
clinically inconsistent finding of positive ANA-IIF in HEp-2 
is that the patient may develop an autoimmune disease in the 
future years. However, some individuals may continue for 
decades with circulating autoantibodies without developing 
any signal of autoimmune disease.8
It is essential to better characterize a positive ANA-IIF 
in HEp-2 cell by searching for hallmark antibodies proper to 
autoimmune pathologies by specific techniques. This evalua-
tion should be supported by clinical or laboratorial evidence 
of a systemic autoimmune disease. Additionally to clinical 
examination, it is important to check possible changes in blood 
count, urine, C-reactive protein and erythrocyte sedimentation 
rate (vHS), which may be considered extensions of the clinical 
exam. In some cases, analyzing hepatic and muscular enzymes 
may be valid. vague symptoms, like arthralgias and asthenia, 
with normal general laboratory tests are not sufficient to pro-
vide support for a laboratorial finding of ANA-IIF in HEp-2 
in low titer and with low specific fluorescence pattern. In such 
cases, common sense and follow-up of the patients with regular 
visits may be the best  decision.
The first two Consensuses contributed to improve readings 
and interpretation of ANA-IIF using HEp-2 patterns by the 
definition of morphological criteria to be followed during the 
reading of test, and by the establishment of a combination cri-
teria including the main groups (nucleus, nucleolus, cytoplasm, 
mitotic apparatus and mixed). Information on main clinical 
associations of different patterns was approached and a new 
terminology was suggested so that the test would express its 
diagnostic dimension.
After the second Consensus, some questions arose requiring 
more discussion and better orientation. One of the problems 
observed concerns the classification of homogeneous nuclear 
pattern regarding the nucleolus reactivity and the mixed pattern 
classification, approaching multiple reactivities in the same 
group, e.g., a pattern with two or more autoantibodies against 
nuclear antigens. Another relevant aspect was the need to ad-
vice about substract heterogeneity, beginning with conjugate 
titer. Since some laboratories are not familiarized with titering 
the conjugate against an absolute or consensual pattern, the 
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same test carried out in kits by different brands may present 
different titers. These problems, as a whole, are responsible 
for heterogeneity in results among several laboratories and 
should be deeply discussed. 
Finally, along these two years, there was a need to review 
clinical associations of different patterns established in the 2nd 
Consensus. Thus, the Third Brazilian Consensus for autoanti-
bodies Screening in HEp-2 Cells (ANA) intended to evaluate 
the difficulties in the accomplishment of the 2nd Consensus 
recommendations that took place in the year of 2002, to discuss 
strategies for quality control of the assay and to promote an 
update for the clinical associations of the several immunoflu-
orescent patterns.
METHOD OF WORk
Several ANA experts from university centers and private labo-
ratories from different areas in Brazil joined the workshop in 
Goiânia on April 13 and 14, 2008, with the purpose of discus-
sing and approving the recommendations for standardization, 
interpretation and use of the test by physicians. Commercial 
representatives of different ANA slide brands were also invited 
as listeners to ANA-IIF in HEp-2 test.
The group approached problems like the need for test 
quality control, definition of some controversial aspects in 
the classification proposed in the 2nd Consensus, report of 
new fluorescence patterns and review of clinical associations. 
These problems were presented to members and widely dis-
cussed in order to get a consensus among several participants. 
discussions were based on previous review of the literature 
concerning different subjects, as well as presentation of their 
own data. 
GENERAL RECOMMENDATION
Nucleolus classification according to 
homogeneous nuclear pattern becomes negative
The 3rd Consensus reaffirms the current classification of fluores-
cence patterns in four cell structures (cytoplasm, nucleus, nu-
cleolus and mitotic apparatus). Additionally, some definitions 
were done for some possible ambiguous or vague situations. 
In cases where nucleus is uniformly stained and nucleolus 
region is not highlighted, the Consensus members understand 
that there is no essential reactivity against nucleolus; therefore, 
it should be described as “negative”. Obviously, nucleolus 
will also be described as “negative” in cases where it is not 
stained. When there is a nuclear pattern, nucleolus will only 
be described as “positive” when its stain becomes visible over 
the nucleus stain. The example below showing homogeneous 
nuclear pattern report is recorded:
• Patient: F.C.O.F.
• Assay: antibody screening against cell antigens (ANA)
• Nucleus: Positive.
• Nucleolus: Negative.
• Cytoplasm: Negative.
• Mitotic apparatus: Negative.
• Chromosomal metaphase plate: Positive
• Pattern: Homogeneous nuclear
Mixed patterns
Mixed Patterns definition was corrected. Every case where 
different staining for cellular structures (nucleus, nucleolus, 
cytoplasm or mitotic apparatus) or different fluorescence 
patterns in one cell structure was classified as mixed pattern. 
Thus, for example, NuMA-1 pattern is considered a mixed 
pattern, because the nucleus and mitotic apparatus are stained. 
Another example is represented by a serum with an autoanti-
body mixture that simultaneously stain the nucleus with a fine 
speckled pattern and centromere speckled pattern. 
Speckled nuclear pattern with separate dots
The 3rd Consensus changed the decision of the 2nd Consensus 
about the need for subclassification of the number of dots in 
speckled nuclear pattern with isolate dots in >10 and <10. 
Pattern terminology has been established as speckled with 
isolated dots. This change happens because the number of 
nuclear stained bodies by anti-p80-coilin and anti-sp-100 
antibodies varies according cell substrate in use. Although, 
in most cases, expert observer may safely suggest the most 
probable autoantibody, the number of dots per nucleus is not 
an absolute criterion.
Non-characterized patterns or 
patterns with new features
Consensus members acknowledge that there are non-charac-
terized patterns or patterns with no defined characteristics in 
the existing classification. In these cases, recommendation is 
to describe morphologically the pattern observed and to add a 
note specifying that it is not part of the Consensus terminology 
and that its immunologic and clinical associations have not 
been defined yet. In such cases, it is essential that the labora-
tory tests this new proposed pattern in commercial kit under a 
different brand than the one where the pattern was originally 
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observed, avoiding human conditions that could result a false 
interpretation.
Two new fluorescence patterns were communicated by few 
Consensus members. Many other members declared they had 
already observed such patterns. 
The first one is a nuclear fine speckled immunofluorescent 
pattern, with an almost homogeneous texture and with homo-
geneously stained metaphase plate. Its clinical association and 
immunological identity are not defined. Its importance comes 
from the fact that it may be easily confused with a dense fine 
speckled pattern and a homogeneous pattern (Figure 1). 
The second is a cytoplasmatic rod- and ring-shaped pat-
tern which is apparently associated to HCv infection. There 
are ongoing studies to establish its immunological identity 
(Figure 2).
As they are not definitely characterized, these two new 
patterns have been considered preliminary and the 3rd Con-
sensus recommended that both patterns have to be completely 
characterized and presented in the next meeting.
Genetically modified cell-based substracts
The 3rd Consensus did not discuss any systematic study with 
genetically modified cell substracts; this could be a possible 
topic for the next meetings. 
qUALITy CONTROL
The Third Consensus promotes and recommends strategies 
for quality control. This recommendation aims at facing 
difficulties to assure test quality due to specialized trained 
professionals needs, heterogeneity of commercial kits and non-
standardization of optical equipment at laboratories. Among 
institutional quality programs, the following programs were 
mentioned: College of American Pathologists (CAP) and edu-
cational program for ANA-IIF in HEp-2 at Controlab. Other 
programs and reagents for quality control were also mentioned, 
such as PCQAUTO by GMK diagnósticos, Conexão HEp-2 
by Hemagen diagnósticos and the blade FITC-QC® by ALKA 
Tecnologia em diagnósticos. 
It was also recommended the titration of conjugate as a 
fundamental measure to adjust the amount of fluorochrome 
according to the lamp power, matching the different depart-
ments. This procedure should also be performed for every new 
kit in a different lot. This titration maintenance in kits from the 
same lot may be performed using low intensity controls. In this 
item, it is useful to use commercial slides with pre-calibrated 
Continue
Figure 1. (A) Nuclear fine speckled tending to be homogeneous. Cells present 
nucleoplasm with finely speckled texture with homogeneous trend and stained 
metaphase plate in the same texture. This pattern should not be confused with 
homogeneous nuclear pattern and dense fine speckled pattern, because there is no 
reactivity against native DNA and LEDGF/75Kda protein, respectively. In figures 
B and C may be observed Homogeneus nuclear pattern and dense nuclear fine 
speckled pattern, respectively.
C - Dense nuclear fine speckled
B - Homogeneous nuclear
A - Nuclear fine speckled tending to be homogeneous
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microsphere for different fluorescence intensity and that may 
be used for training and internal calibration of reading.
In order to stimulate the achievement of authentic results, 
the 3rd Consensus recommends the laboratories to take part at 
quality control programs and systematically perform technical 
quality control. It is fundamental to remember that IIF reaction 
depends on five factors: Optical system (microscope), light 
power (20, 50 or 100W), conjugate concentration, control 
serum of minimum reactivity (1/80) and observer.
Conjugate concentration allows matching different optical 
systems, different power lights and observer’s reading. For 
example, if the light power is low, a more concentrate conjugate 
use is recommended in order to get the same fluorescence of a 
light with more power. In order to establish the ideal concen-
tration of conjugate (conjugate’s titer), one should use titration 
technique in blocks where several dilutions of conjugate are 
crossed with several concentrations of a reference serum, 
searching the higher dilution of conjugate that is capable to 
reproduce nominal titer of reference serum.
This reference serum may be included with the kit and the 
laboratory will begin to be based on the optical, light and reader 
system according to patterns established by the manufacturer. 
This reference serum may be commercially acquired from 
quality control institutions or the laboratory will be able to 
send its serum to a laboratory of its reference and, then, with 
the results, start to consider this laboratory as reference. Once 
the first reference is done, the laboratory may store weekly 
aliquots of serum of titers established in this laboratory. 
The laboratory should keep in its serum bank samples for 
controlling with minimum reactivity titer (1/80), to be diluted 
Figure 2. Cytoplasmatic rod- and ring-shaped pattern Apparently associated with 
HCv infection and interferon treatment. Target antigens of these antibodies are 
under definition.
Cytoplasmatic in rods and rings
in 1/40, 1/80, 1/160 and 1/320. At each daily set, the labora-
tory should process the low control and consider this set valid 
if titer variation is more or less one dilution. If any control 
inconformity is seen, for example, if a sample with average 
titer of 1/80 is negative, this set should be considered invalid. 
Using the minimum reactivity control (1/80), a set of tests will 
only be considered valid after reading one titer at more or less 
80. In case of a decrease over 1 titer, the system is probably 
unstable. It is recommended to first verify if there was any 
problem in the aliquot stored; in this case, repeat the test with 
the aliquot stored the week before. If in the end of repetition, the 
titer found was the expected, we may conclude that the control 
aliquot used was deteriorated. If the new aliquot also presented 
a titer decrease of more than one dilution, we should check 
the optical system (UV filter deterioration, buffered glycerin 
in the objective lens and lamp performance). If no change is 
found in these components and in the number of hours of the 
lamp use, the most probable cause is conjugate degradation; 
if so, conjugate should go through  a new titration process, as 
described before.
Notes
1. It is recommended to perform conjugate 
control every 15 days. 
2. When a new kit is opened, a new titration 
of conjugate should be performed. 
3. Microscope’s objective lens and filters 
interfere in the definition of conjugate titer 
and should be periodically checked.
4. Additionally to checking the time of the lamp, it is 
necessary to check if the lamp is in the center. It can 
be performed by placing a white paper sheet on the 
microscope table and using the objective lens 10 to see 
if the lamp is in the center. If you notice any dark part 
of the field, adjust it by using the following bottoms: 
left-right center, up and down center, and lamp focus.
CLINICAL ASSOCIATIONS AND 
PATTERN DESCRIPTION
Members of the 3rd Consensus proceeded to a wide discussion 
for validation and reevaluation of clinical and immunological 
associations about ANA-IIF patterns in HEp-2. Recommen-
dations are listed in Table 1.
Most of the associations above had been accepted by 
general agreement by the Consensus members. In rare non-
unanimous cases, the majority opinion prevailed.
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Table 1
ANA pattern by IIF using HEp-2 substrate, description, main related autoantibodies and more frequent clinical associations
Patterns Description Clinical relevance for autoantibodies
Nuclear, type nuclear 
membrane
Pattern characterized by fluorescence in the whole nuclear 
membrane (it may be issued with additional information 
in continuous or speckled aspect). No fluorescence is 
seen in nucleolus and cytoplasm; dividing cell presents 
no fluorescence in all stages. Do not confuse with the old 
peripheral pattern seen in rat’s liver where double helix 
DNA was fixed to nuclear membrane protein, giving its 
characteristic aspect.
Antibody against nuclear envelope proteins. Primary biliary 
cirrhosis, autoimmune hepatitis, rarely associated to rheuma-
tic diseases. Some forms of systemic lupus erythematosus and 
linear scleroderma, antiphosoholipid syndrome. Such pattern 
may be observed in individuals without apparent evidence of 
autoimmunity, especially when in low titers.
Anti-gp210 antibody is specific for primary biliary cirrhosis.
Other autoantibodies associated to this pattern: anti-p62 
(nucleoporin), anti-lamins A, B, and C, anti-LBP.9
Homogeneous nuclear Homogeneous and even staining of the nucleus It is not 
possible to distinguish the nucleolus and it is considered 
non reagent. Chromosome metaphase plate with intense 
staining, hyaline aspect, with homogeneous decoration of 
chromosomes, also positive in anaphase and telophase. 
Cytoplasm normally non fluorescent.
Anti-DNA double stranded antibody. Indication of  systemic 
lupus erythematosus
Antihistone antibody. Indication for drug-induced systemic lu-
pus erythematosus, idiopathic systemic lupus erythematosus, 
rheumatoid arthritis, juvenile idiopathic arthritis (oligoarticular 
and uveitis), Felty’s syndrome and autoimmune hepatitis.10
Anti-chromatin antibody (DNA/histone, nucleosome). 
Systemic lupus erythematosus.11
Nuclear coarse speckled Nucleoplasm with coarse speckles, heterogeneous in size 
and brightness, highlighting some bigger and brighter gra-
nules (1 to 6/nucleus) corresponding to Cajal body, rich in 
spliceosome ribonucleoproteins. Nucleolus, mitotic cells 
and cytoplasm are not stained.
Anti-Sm antibody. Indicative of systemic lupus erythema-
tosus.12
Anti-Rnp antibody. Mandatory criteria in diagnosis of mixed 
connective tissue disease, also present in systemic lupus 
erythematosus and systemic sclerosis.12
Nuclear fine speckled Finely granulated nucleoplasm. Nucleolus, mitotic cells and 
cytoplasm are not stained.
Anti-SS-A/Ro antibody. Primary Sjögren’s syndrome, systemic 
lupus erythematosus, neonatal lupus, and subacute cutaneous 
lupus, systemic sclerosis, polymyositis and Primary biliary 
cirrhosis.13
Anti-SS-B/La antibody. Primary Sjögren syndrome, systemic 
lupus erythematosus, neonatal lupus.13
Dense nuclear fine speckled Nucleoplasm of a cell in interphase stage present as a 
peculiar speckle, with heterogeneous distribution, not stai-
ned nucleolus. Mitotic cells present an intense and rough 
speckled decoration of chromosomes in metaphase plate. 
Cytoplasm not stained.
Antiprotein p75 antibody (transcription cofactor) named 
LEDGF/p75. one of the most frequent patterns found in 
routine, which clinical correlation has not been completely 
established, and it is frequently found in individuals with no 
objective evidence of a systemic disease. Rarely found in 
rheumatic diseases, autoimmune diseases and specific and 
non specific inflammatory processes. There are reports in 
literature about finding such pattern in patients with interstitial 
cystitis, atopic dermatitis, psoriasis and asthma.14
Speckled nuclear with 
isolated dots
Nucleoplasm presents isolated fluorescent dots (additio-
nal information: the number of dots ≥10 or < 10 dots per 
nucleus). Nucleolus, mitotic cells and cytoplasm are not 
stained.
Anti-p80 coilin antibody. No clinical association defined.15
Anti-Sp100 – anti-p95 antibody. Described especially in 
primary biliary cirrhosis.16
Such initiative shows the intense activity in auto anti-
bodies research, and particularly, in antinuclear antibody, 
in Brazil. We should emphasize that this activity has been 
providing a progressive and remarkable development in 
our scientific and professional community, establishing an 
independent national position about the way to perform 
and interpret assay to screen autoantibodies using HEp-2 
cells. The physicians and consequently their patients has 
also benefited of this laboratory test. Finally, it is necessary 
to explain that this is a continuous and progressive process 
and it depends on the interaction of the whole community 
involved in several steps of this process.
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Nuclear speckled centromere 46 bright speckles spread over the nucleus of interphase 
cells. Nucleolus and cytoplasm not stained. Mitotic cells 
presents dots concentration in metaphase plate. 
Anticentromere antibody (CENP-A, CENP-B and CENP-C 
proteins). CREST -systemic sclerosis (calcinosis, Raynaud’s 
phenomenon, esophageal dysmotility, sclerodactyly and te-
langectasia), primary biliary cirrhosis, and Sjögren’s syndrome. 
Rarely observed in other autoimmune diseases. It may precede 
CREST for many years.17,18 
Pleomorphic nuclear speckled Nucleoplasm is totally not stained in G1 cell interphase, 
becoming speckled with grains ranging from coarse, fine to 
dense fine, at the time the cell passes to phases S and G2. 
Nucleolus and cytoplasm not stained. 
Proliferating cell nuclear antigen (anti-PCNA). Specifically 
found in patients with systemic lupus erythematosus.19
Homogenous nucleolar evenly bright fluorescence nucleolus, mitotic cells and 
cytoplasm not stained.
Antihistone anti-To/Th. Occur s in systemic sclerosis.20
Antinucleolin antibody. Very rare, describe in systemic lu-
pus erythematosus, graft-versus-host disease and infectious 
mononucleosis.
Anti-B23 antibody (nucleophosmin). Described in systemic 
sclerosis, some types of cancer, antiphospholipid syndrome 
and graft-versus-host disease.
Clumpy nucleolar Nucleolus presents tight clusters of fluorescent granules (such 
as a bunch of grapes). Cytoplasm and nucleus not stained, 
mitotic cell is amorphous, with soft color around metaphase 
plate chromosomes.
Antifibrillarin antibody (U3-nRNP). Related to systemic 
sclerosis, especially with severe visceral damage, such as 
pulmonary hypertension.21
Speckled nucleolar
 
Fine and discrete speckles in the nucleolus; 5-10 different 
and brilliant dots along chromosomal metaphase plate. 
Cytoplasm and nucleus not stained.
Anti-NOR 90 antibody. Initially described in systemic scle-
rosis. Today described in other autoimune diseases, however 
without clinical relevance defined.21
Polymerase I anti-RNA antibody. Diffuse systemic sclerosis 
with trend to visceral damage, more frequent and severe.21
Anti-ASE antibody (ERCC-1 antisense). Frequently found 
associated to anti-NOR-90 antibodies. The most frequent 
association seems to be systemic lupus erythematosus.
Linear cytoplasmatic fibrilar
 
Stressed fibers forming cytoskeleton decorated, crossing the 
whole extension of the cell, not respecting nuclear limits. 
Nucleus and nucleolus not stained.
Anti-actin antibody. Found in liver diseases: autoimmune 
hepatitis, cirrhosis.
Antimyosin antibody. Hepatitis C, hepatocarcinoma, myas-
thenia gravis. When in low or moderate titers, may have no 
clinical relevance.22,23
Filamentar cytoplasmatic 
fibrillar
Decoration with filaments with unipolar or bipolar accentu-
ation related to nuclear membrane. Nucleus and nucleolus 
not stained. 
Anti-vimentin and anti-keratin antibody. Anti-keratin antibody 
is the most important antibody in alcohol-related hepatic 
disease. Described in several inflammatory and infectious 
diseases. When in low or moderate titers, may have no cli-
nical relevance.24
Segmentary cytoplasmatic 
fibrilar
 
Only short stressed fiber segments are fluorescent. Nucleus 
and nucleolus not stained. In mitotic cells, we can eventu-
ally observe multiple fluorescent grains corresponding to 
globular form of cytoplasm protein.
Anti alpha-actinin, anti-vinculin and anti-tropomyosin. 
Antibodies found in myasthenia gravis, Crohn’s disease and 
ulcerative colitis. When in low or moderate titers, may have 
no clinical relevance.24
Polar speckled cytoplasmatic
 
This is also a mandatory report, because it makes evident 
Golgi apparatus. Decoration is only cytoplasmatic in grou-
ped dots in perinuclear situation on one pole of the nucleus. 
Nucleolus, mitotic cells and nucleus are not stained.
Anti-golgin antibody (Golgi apparatus cistern). Rare in sys-
temic lupus erythematosus, primary Sjögren syndrome and 
other systemic autoimmune diseases. Reported in idiopathic 
cerebellar ataxia, paraneoplasic cerebellar degeneration 
and viral infection by Epstein Barr virus (EBV) and human 
immunodeficiency virus (HIV). When in low or moderate 
titers, may have no clinical relevance.25,26
Speckled cytoplasmatic 
with isolated dots 
Defined dots with variable number for the whole extension 
of cytoplasm. Nucleolus, mitotic cells and nucleus are not 
stained.
Anti-EEA1 antibody and anti-phosphatidylserine. No clinical 
associations well defined.
Anti-GWB antibody. Related to primary Sjögren syndrome, al-
though also observed in several other clinical conditions.27
Continue
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Fine dense speckled 
cytoplasmatic 
Fine dot, dense and confluent fluorescence, almost homo-
geneous. Nucleus is not stained, but may present a slight 
homogeneous decoration in nucleolus area. Mitotic cell is 
not stained. In case of concomitant fluorescence of cyto-
plasm and nucleolus, pattern is classified as mixed.
Anti-PL7/PL12 antibody. This pattern may be rarely associated 
with antibodies found in polymyositis.20
Antiribosomal P protein antibody. This pattern is found in 
systemic lupus erythematosus.28
Fine speckled cytoplasmatic Fine speckles covering the whole cytoplasm. Mitotic cell 
and nucleolus not stained.
Histidil anti tRNA synthetase antibody (Jo1). Marker antibody 
of polymtositis in adults. Rarely described in dermatomyositis. 
Other anti tRNA synthetases antibodies may generate the 
same pattern.20
 Reticular speckled 
cytoplasmatic
Large and irregular speckles concentrated in the perinu-
clear region and extended in lower density to the rest of 
the cytoplasm. Nucleolus, mitotic cells and nucleus are 
not stained.
Antimitochondrial antibody. Primary biliary cirrhosis ma-
rker. Rarely found in systemic sclerosis. Due to relatively 
common finding of a similar pattern and not related to 
antimitochondrial antibodies, specific test confirmation is 
fundamental.29,30
Mitotic apparatus 
type centriole
In interphase cells, fluorescence is confined to a single sphe-
re close to the nucleus, dividing in two and migrating to the 
opposite pole of nucleus as the cell starts to split.
Anti-alpha-enolase antibody. In low titers, there is no clinical 
association. In high titers, it may be associated with systemic 
sclerosis.
Mitotic apparatus type 
intercellular bridge 
Antigens forming the union between mother/daughter cells 
in the end of telophase. They may be observed with intense 
fluorescence in cytoplasmatic tip that will suffer cleavage 
in the end of cell division.
Anti-beta tubulin antibody. May be found in systemic lupus 
erythematosus and Mixed Connective Tissue Disease. Other 
not well defined antibodies may generate the same pattern. 
Associated with several auto immune conditions with low 
specificity, with clinical relevance only in high titers.22
Mitotic apparatus type 
mitotic spindle (NuMa-2)
 
Interphase cells showed no nuclear or cytoplasmic staining, 
but mitotic cells had brightly stained poles and spindles. 
At telophase, staining shifted to the midbody and the in-
tercellular bridge. 
Anti-HsEg5/NuMA-2 antibody. Associated with several auto 
immune conditions with low specificity, with clinical rele-
vance only in high titers.36
Mixed, Nuclear fine speckled 
type with fluorescence 
in Mitotic apparatus
 
Cells in interphase present a stained nucleus with a very fine 
speckled, generally, in high titer. Miotic cells in metaphase 
and anaphase present well define and delicate location of 
pericentromeric region and proximal parts of mitotic spindle. 
In telophase, the staining shifted from the centrosomes to the 
reforming nuclei and no stain in intercellular bridge.
Anti-NuMa1 antibody. Associated to Sjögren’s Syndrome 
and may occur also in other auto immune or chronic in-
flammatory conditions. When in low or moderate titers, may 
not be associated with the objective evidence of systemic 
inflammatory disease.32
Mixed, type homogeneous 
nucleolar and coarse speckled 
Interphase cells present a stained nucleus with a coarse spe-
ckled and homogeneously reddish nucleolus. In metaphase, 
there is stain around metaphase plate.
Anti-KU antibody. Marker of polymtositis and systemic scle-
rosis overlap. May occur in systemic lupus erythematosus 
and scleroderma.33
Mixed, type fine nuclear and 
nucleolar fine speckled with 
stained metaphase plate 
 
Interphase cells present a stained nucleus with a fine 
speckled form and nucleolus is also highlighted with fine 
speckled pattern. In metaphase, metaphase plate presents 
fine speckled pattern.
Anti-DNA Topoisomerase I antibody (Scl-70). Associated with 
systemic sclerosis, diffuse form, presenting with more visceral 
damage. More rarely in CREST syndrome and overlap.34
Mixed, type speckled nucleolar 
and nuclear fine speckled
Interphase cells present a stained nucleus with a fine 
speckled form and nucleolus is also highlighted with fine 
speckled pattern (individual dots). Cytoplasm is not stai-
ned. In metaphase, 5 to 10 isolated bright dots are seen in 
metaphase plate, corresponding to nucleolus organizing 
regions (NOR). 
Anti-RNA Polymerase I and II antibodies. These two autoanti-
bodies usually appear together, and RNA pol. I is responsible 
for nucleolar distribution and in NOR, while RNA pol. II res-
ponds for nuclear distribution. Anti-RNA pol. I is considered 
a systemic sclerosis marker and anti-RNA pol. II appears in 
several autoimmune conditions.34
Mixed, type fine dense 
speckled cytoplasmatic 
nucleolar to homogeneous 
nucleolar
Nucleus is totally not stained and nucleolus is poorly 
stained. Cytoplasm presents strong stain with very fine and 
very dense speckled, almost homogeneous. Mitotic cells 
are not stained.
Anti-rRNP antibody (anti-ribosomal P protein). systemic 
lupus erythematosus marker and more frequently related 
to lupus psychosis. Also seems to be related to the disease’s 
activity.28,35
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